We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Protagenic Therapeutics Inc (PTIX) USD0.0001

Sell:$1.25 Buy:$1.51 Change: $0.0101 (0.68%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$1.25
Buy:$1.51
Change: $0.0101 (0.68%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$1.25
Buy:$1.51
Change: $0.0101 (0.68%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Contact details

Address:
149 FIFTH AVENUE, SUITE 500
NEW YORK
10010
United States
Telephone:
+1 (212) 9948200
Website:
https://protagenic.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PTIX
ISIN:
US74365N2027
Market cap:
$6.16 million
Shares in issue:
4.44 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Garo Armen
    Executive Chairman of the Board
  • Alexander Arrow
    Chief Financial Officer
  • Andrew Slee
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.